News
Reflecting on the Trials@Home journey – shaping the future of decentralised clinical trials
Last week in Utrecht, the Trials@Home consortium gathered for its Annual Consortium Meeting and its Closing Event — a moment to celebrate achievements, share lessons learned, and look ahead to the future of decentralised clinical trials (DCTs).
At Lygature, we are proud to have played a central role in this project – from coordinating multi-partner collaboration and managing stakeholder and partner communications, to helping craft the governance, partnership and sustainability frameworks, as well as the Privacy and Regulatory elements that underpin the project. Through our contribution, we’ve helped ensure that cross-sector teams — academia, industry, patient organisations and regulatory bodies — could work together effectively toward enabling more participant-centred, accessible clinical research.
Looking forward, we’ll be building on this foundation by supporting the uptake of these learnings across new trials, facilitating implementation of DCT approaches, and helping translate the recommendations into practice.
The Trials@Home consortium has now published a set of recommendations for the implementation of decentralised clinical trial approaches, covering methodological, regulatory, ethical, operational and social aspects. These recommendations provide a roadmap for making DCTs more robust, participant-friendly and future-ready.
“It’s been inspiring to see how collaboration across academia, industry and patient organisations has transformed what began as an ambitious idea into concrete recommendations for future-ready clinical research,” said Olenka van Ardenne, Senior Partnership Leader at Lygature. “Lygature will continue supporting partnerships that build on Trials@Home’s foundations to make clinical research more accessible and patient-centric.”
Herman Verheij, Senior Partnership Leader at Lygature, added: “Our role in stitching together the diverse partner ecosystem has not only been about delivering to the project but also about seeding a new way of thinking about how trials can be designed, conducted and sustained in a decentralised fashion.”
We look forward to continuing this journey – turning the lessons from Trials@Home into lasting impact for patients, researchers and the healthcare ecosystem at large.